US 12,145,930 B1
4-thiazolidinone derivatives as EGFR inhibitors for anti-tumor activity
Ibrahim Taha Radwan, Al-Ahsa (SA); Mohamed Marzok, Al-Ahsa (SA); Adel Alsheikh Mubarek, Al-Ahsa (SA); and Abdelfatah Seleim, Al-Ahsa (SA)
Assigned to KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed by KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed on Feb. 15, 2024, as Appl. No. 18/443,136.
Int. Cl. C07D 417/12 (2006.01); A61K 9/51 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61P 35/00 (2006.01); C07D 277/54 (2006.01); C07D 417/06 (2006.01)
CPC C07D 417/12 (2013.01) [A61K 9/5123 (2013.01); A61K 9/5161 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61P 35/00 (2018.01); C07D 277/54 (2013.01); C07D 417/06 (2013.01)] 19 Claims
 
1. A compound having the formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein:
R is selected from the group consisting of hydrogen, 2-hydroxy-5-((E)-phenyldiazenyl)benzylidene, 2-hydroxy-5((4-methoxyphenyl)diazinyl)benzylidene, (dimethylamino)methylene, and an optionally substituted CHAr substituted with one or more substituents independently selected from the group consisting of hydrogen, hydroxy, methoxy, a halogen, naphthalene, a 1H-indol-3-yl, and dimethyl amino; 5-((4-chlorophenyl)-2-hydroxybenzylidene); and (dimethylamino)methylene.